The department and the drugmaker said they would leverage an existing partnership to develop monoclonal antibodies for 2019-nCoV. A drug made by Gilead Sciences for Ebola is also being tested as a treatment for the rapidly spreading virus.
A greater willingness to embrace new technologies has made it easier to develop vaccines against the 2019-nCoV virus, while newer drugs have also shown signs of efficacy, experts said. More than 17,000 were confirmed infected worldwide as of Monday, the WHO reported.
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.